Russell Investments Group’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $273K | Buy |
196,561
+2,824
| +1% | +$3.88K | ﹤0.01% | 2740 |
|
|
2025
Q4 | $312K | Buy |
193,737
+61,301
| +46% | +$128K | ﹤0.01% | 2665 |
|
|
2025
Q3 | $362K | Buy |
132,436
+33,613
| +34% | +$112K | ﹤0.01% | 2609 |
|
|
2025
Q2 | $360K | Sell |
98,823
-9,329
| -9% | -$25.6K | ﹤0.01% | 2464 |
|
|
2025
Q1 | $208K | Sell |
108,152
-2,778
| -3% | -$5.67K | ﹤0.01% | 2582 |
|
|
2024
Q4 | $211K | Sell |
110,930
-59,444
| -35% | -$103K | ﹤0.01% | 2523 |
|
|
2024
Q3 | $225K | Sell |
170,374
-5,428
| -3% | -$7.25K | ﹤0.01% | 2483 |
|
|
2024
Q2 | $179K | Hold |
175,802
| – | – | ﹤0.01% | 2503 |
|
|
2024
Q1 | $322K | Sell |
175,802
-6,259
| -3% | -$10K | ﹤0.01% | 2343 |
|
|
2023
Q4 | $226K | Sell |
182,061
-5,689
| -3% | -$5.8K | ﹤0.01% | 2408 |
|
|
2023
Q3 | $214K | Sell |
187,750
-1,068
| -0.6% | -$1.37K | ﹤0.01% | 2475 |
|
|
2023
Q2 | $173K | Hold |
188,818
| – | – | ﹤0.01% | 2501 |
|
|
2023
Q1 | $106K | Sell |
188,818
-3,165
| -2% | -$2.42K | ﹤0.01% | 2578 |
|
|
2022
Q4 | $111K | Sell |
191,983
-3,932
| -2% | -$1.23K | ﹤0.01% | 2653 |
|
|
2022
Q3 | $60K | Sell |
195,915
-29,725
| -13% | -$11.7K | ﹤0.01% | 2728 |
|
|
2022
Q2 | $78K | Sell |
225,640
-30,327
| -12% | -$12.7K | ﹤0.01% | 2695 |
|
|
2022
Q1 | $182K | Sell |
255,967
-60,080
| -19% | -$129K | ﹤0.01% | 2481 |
|
|
2021
Q4 | $713K | Sell |
316,047
-90,633
| -22% | -$247K | ﹤0.01% | 2312 |
|
|
2021
Q3 | $1.17M | Sell |
406,680
-52,400
| -11% | -$150K | ﹤0.01% | 2120 |
|
|
2021
Q2 | $1.74M | Buy |
459,080
+6,671
| +1% | +$22.5K | ﹤0.01% | 2001 |
|
|
2021
Q1 | $1.53M | Buy |
452,409
+8,620
| +2% | +$31K | ﹤0.01% | 2028 |
|
|
2020
Q4 | $1.24M | Buy |
443,789
+249,812
| +129% | +$729K | ﹤0.01% | 2018 |
|
|
2020
Q3 | $484K | Sell |
193,977
-73,911
| -28% | -$649K | ﹤0.01% | 2407 |
|
|
2020
Q2 | $3.63M | Buy |
267,888
+151,768
| +131% | +$1.57M | 0.01% | 1291 |
|
|
2020
Q1 | $880K | Buy |
116,120
+2,759
| +2% | +$21.5K | ﹤0.01% | 1905 |
|
|
2019
Q4 | $716K | Buy |
+113,361
| New | +$539K | ﹤0.01% | 2272 |
|
|
2019
Q2 | – | Sell |
-53,960
| Closed | -$442K | – | 2855 |
|
|
2019
Q1 | $442K | Buy |
53,960
+1,628
| +3% | +$11.2K | ﹤0.01% | 2386 |
|
|
2018
Q4 | $289K | Buy |
52,332
+21,900
| +72% | +$171K | ﹤0.01% | 2501 |
|
|
2018
Q3 | $268K | Buy |
30,432
+6,860
| +29% | +$61.4K | ﹤0.01% | 2586 |
|
|
2018
Q2 | $236K | Sell |
23,572
-22,637
| -49% | -$227K | ﹤0.01% | 2601 |
|
|
2018
Q1 | $440K | Buy |
46,209
+6,663
| +17% | +$93.2K | ﹤0.01% | 2508 |
|
|
2017
Q4 | $612K | Sell |
39,546
-38,094
| -49% | -$632K | ﹤0.01% | 2363 |
|
|
2017
Q3 | $1.53M | Buy |
77,640
+7,571
| +11% | +$116K | ﹤0.01% | 1928 |
|
|
2017
Q2 | $1.01M | Sell |
70,069
-19,398
| -22% | -$246K | ﹤0.01% | 2114 |
|
|
2017
Q1 | $823K | Buy |
89,467
+78,742
| +734% | +$769K | ﹤0.01% | 2205 |
|
|
2016
Q4 | $111K | Buy |
+10,725
| New | +$92.4K | ﹤0.01% | 2847 |
|
Other funds holding AKBA
VCM
VPM
Russell Investments Group's AKBA Position: Q1 2026 in Review
Russell Investments Group increased its Akebia Therapeutics (AKBA) stake by 1.5% in Q1 2026, buying an estimated $3.88K and bringing the position to 196,561 shares worth $273K. The position accounts for ﹤0.01% of the portfolio, ranked #2740.
Russell Investments Group first reported a position in AKBA in Q4 2016 and has held it in 36 quarters since. The position peaked at $3.63M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Russell Investments Group held 196,561 shares of Akebia Therapeutics worth $273K as of Q1 2026.
- Russell Investments Group bought 2,824 Akebia Therapeutics shares in Q1 2026, an estimated $3.88K.
- Akebia Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q1 2026, its #2740 holding.
- Russell Investments Group first reported a position in Akebia Therapeutics in Q4 2016 and has held it in 36 quarters since.
- Russell Investments Group's Akebia Therapeutics position peaked at $3.63M in Q2 2020.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.